Article Details
Retrieved on: 2017-12-12 20:22:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>ROCKVILLE, Md.--(BUSINESS WIRE)--<b>Immunomic Therapeutics</b>, Inc. (ITI), a privately held, Maryland-based biotechnology company, is pleased to welcome Drew Pardoll, MD, Ph.D., Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins School of Medicine, as a new ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here